DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Ford HE. et al.
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Lancet Oncol 2014;
15: 78-86
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.